Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q2 2023 · 10-Q
Revenue$0.00$0.00no prior Q2 2022 on file Net Income-$2.62M-$2.62MN/M vs Q2 2022 EPS Diluted-$1.33-$1.33N/M vs Q2 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Operating Cash Flowderived-$18,532N/M ended Feb 28, 2023 · filed Apr 14, 2023 · 45 d after period end